Printer Friendly

EDITEK BEGINS MARKETING AND DISTRIBUTION OF VERDICT COCAINE ONE-STEP DRUG TEST

 BURLINGTON, N.C., Feb. 22 /PRNewswire/ -- EDITEK (AMEX: EDI.EC) announced that it began shipment today of its VERDICT(R) one-step drugs of abuse tests. The first product being shipped is the VERDICT Cocaine test. These state-of-the-art, second generation, on-site tests for drugs of abuse incorporate the unique, proprietary patented technology possessed by EDITEK, Inc.
 EDITEK began preproduction marketing of VERDICT in 1992. The Company has been procuring manufacturing equipment and putting into place a new production and assembly operation for the company's one-step assays, the first of which will be the VERDICT drug assays. The release of the VERDICT Cocaine one-step test will be followed shortly by additional VERDICT one-step drug assays. The Company continues to manufacture and sell the first generation EZ-SCREEN on-site drugs of abuse tests. The market for on-site drug tests is segmenting between the multiple-step, highly sensitive EZ-SCREEN tests and the new, state- of-the-art, second generation, one-step VERDICT drug assays.
 James D. Skinner, President and Chief Executive Officer of EDITEK, stated: "The manufacturing and distribution of the VERDICT Cocaine one-step drug test marks the achievement of a major milestone for our Company. The availability of this product signifies our potential for dramatic growth in the on-site drugs of abuse testing marketplace where our technological leadership is unsurpassed. The investment that we have made in our patented technology and one-step assays as well as the investment made in our state-of-the-art manufacturing operation will reap great rewards as we expand our one-step drugs of abuse business and the other markets served by our Company."
 EDITEK, Inc. is an emerging, biodiagnostic company with patented technology for the performance of rapid, on-site assays including one- step tests. The Company currently has products on market or research and development and supply agreements that address the human/clinical, drugs of abuse, U.S. Department of Defense tests for biological substances, veterinary and agridiagnostics and food safety testing markets.
 -0- 2/22/93
 /CONTACT: Peter J. Heath, Vice President-Finance and Chief Financial Officer of EDITEK, 919-226-6311/
 (EDI)


CO: EDITEK, Inc. ST: North Carolina IN: MTC SU: PDT

CM -- CH001 -- 8893 02/22/93 10:57 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 22, 1993
Words:354
Previous Article:FORD NAMES NEW MANAGER FOR LOUISVILLE ASSEMBLY PLANT
Next Article:HURCO REPORTS FIRST QUARTER RESULTS
Topics:


Related Articles
EDITEK SUES DISEASE DETECTION INTERNATIONAL RELATIVE TO A LICENSE AGREEMENT TERMINATED NEARLY FIVE YEARS AGO
DISEASE DETECTION INTERNATIONAL SEEKS INJUNCTION AGAINST EDITEK
EDITEK WINS PRELIMINARY INJUNCTION ROUND IN COURT
EDITEK, INC. AND RHONE-POULENC DIAGNOSTICS, LTD. ESTABLISH JOINT VENTURE
EDITEK ANNOUNCES INCREASED REVENUES, STRONGER CASH POSITION AND SIGNIFICANT ACHIEVEMENTS FOR FISCAL YEAR 1992
EDITEK, INC., RECEIVES NEW PATENT
EDITEK, INC. BEGINS SHIPPING VERDICT OPIATES ONE-STEP TESTS
EDITEK RECEIVES FDA PRE-MARKET CLEARANCE FOR EZ-SCREEN PCP TEST
EDITEK RECEIVES SECOND VERDICT FDA PRE-MARKET CLEARANCE
EDITEK LAUNCHES EZ-SCREEN(R) PROFILE(TM) DRUGS OF ABUSE PRODUCT

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters